GlassScriptPhysician profile
Meleigh E Groff
NPI 1841814555
$1,487.66
in general payments reported to CMS, 2019-2025
20 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.29 · 2023: $150 · 2024: $567 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $468.83 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $187.61 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $166.78 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $136.11 | 2021-2025 | |
| Dynavax Technologies Corporation | $50.91 | 2025 | Heplisav-B |
| Glaxosmithkline, LLC. | $48.26 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $47.32 | 2023-2025 | |
| Exact Sciences Corporation | $45.11 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.35 | 2024-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $42.27 | 2023-2024 | Gemtesa |
| Zimmer Biomet Holdings, INC. | $40.39 | 2025 | Rosa |
| Daiichi Sankyo INC. | $38.60 | 2023-2025 | Injectafer |
| Stryker Corporation | $31.36 | 2025 | Clottriever Bold Catheter |
| Astrazeneca Pharmaceuticals LP | $28.26 | 2024-2025 | Farxiga, Breztri |
| Inari Medical, INC. | $28.22 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $23.51 | 2025 | Inspire |
| Biogen, INC. | $21.96 | 2024 | Skyclarys |
| Amgen INC. | $15.03 | 2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $14.89 | 2024 | Trintellix |
| Organon LLC | $7.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meleigh Groff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.